Copy
 Sent by MedEngine Oy

Welcome to MedEngine Insight!

When I founded MedEngine some two years ago, the fundamental idea was to create something that didn’t exist: an agency that combines insights from the pharmaceutical and health-tech industries with scientific expertise, creativity, and, most importantly, premium quality service. But that wasn’t all. We also wanted a workplace that is fun and inspiring and would allow us to do things that truly excite us. The launch of Insight is one expression of this founding principle of MedEngine.
 
We’ve already been active bloggers before, but we wanted to do something more. With Insight, we're able to share insights, ideas and inspiration—everything we are excited about—to an even broader audience of pharma and health-tech professionals. We do our best to provide you with high quality content and truly hope that this is something you'll find useful and inspiring.

On this first issue of Insight, Kimmo Pitkänen, Director of the Helsinki Biobank, is sharing his thoughts on the value of biobanks to industry. We also cover other exciting topics ranging from the currently superhot CRISPR-technology to advice for aspiring Medical Science Liaisons, and the importance of Real-World Data and Data Sharing for the pharmaceutical industry.

I hope you enjoy the first issue of Insight. If you have any questions, comments, or suggestions, please drop me a note at tero@medengine.fi.
 
Thanks for reading!



Tero Ylisaukko-oja
Founder and CEO
MedEngine Oy

BIOBANK RESEARCH – WHAT'S IN IT FOR THE INDUSTRY?

by Kaisa Oksanen on March 31st, 2016
During the past year, Finnish biobanks have started several collaboration projects with international pharmaceutical companies. We went to ask Kimmo Pitkänen, Director of the Helsinki Biobank, what the private sector can gain from public biobanks. 
Read more...

DATA SHARING: MAKING CLINICAL TRIALS ACCESSIBLE
AND PHARMA VISIBLE

by Anna Grönholm on March 23rd, 2016
Data sharing can be used to confirm scientific hypotheses and expedite progress in research. In addition to scientific benefit, data sharing is an excellent opportunity for pharmaceutical companies to stand out.
Read more...

ON GENOME EDITING AND PATENT BATTLES – 
EXPLORING THE CRISPR WORLD

by Anna Grönholm on March 8th, 2016
CRISPR, or clustered regularly interspaced short palindromic repeats, as the scientific name goes, is a genome-editing tool that can be used to manipulate genes basically any way you want. But what is so revolutionary about the CRISPR system, and who gets to patent it?
Read more...

FROM A PHD PROJECT TO A WORLD-FAMOUS DATASET – 
THE NORTHERN FINLAND BIRTH COHORT

by Anna Grönholm on February 5th, 2016
The Northern Finland Birth Cohort (NFBC) 1966 started as a study on the health of over 10,000 newborns and their mothers. Since then, large amounts of clinical, genetic, health-related, and other types of data have been collected from the NFBC babies – and this year, this extensively followed up group turns fifty.
Read more...

WHAT ARE MEDICAL SCIENCE LIAISONS MADE OF – 
AND HOW TO BECOME ONE?

by Tero Ylisaukko-oja on December 1st, 2015
Medical Science Liaison (MSL), Medical Science Relations, Medical Manager, Scientific Advisor, Medical Advisor. There are many names for the field-based medical expert role - but how to become one, and preferably a good one?
Read more...

THE NEW CURRENCY IN HEALTHCARE: REAL-WORLD DATA

by Anna Grönholm on November 4th, 2015
The bustle around real-world data (RWD) has increased in recent years. RWD can provide new insights on the benefit-risk ratio throughout a medicinal product’s life cycle, or update our current understanding of medical practices.
Read more...

Hungry for more? Remember to visit the Insight blog!
Share
Tweet
Forward to Friend
Share
Copyright © 2016 MedEngine, All rights reserved.

MedEngine Oy
Lönnrotin puistikko 5 A 1
00120 Helsinki, Finland